Switching α-glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Factors in Type 2 Diabetic Japanese Patients

Overview

Journal Drugs R D

Specialty Pharmacology

Date 2014 Aug 1

PMID 25079671

Citations 2

Authors

Natsuyo Hariya

Kazuki Mochizuki

Seiya Inoue

Miyoko Saito

Masahiro Fuchigami

Toshinao Goda

Takeshi Osonoi

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: In this study we examined the effects of switching α-glucosidase inhibitors (α-GI) from acarbose or voglibose to miglitol on glucose fluctuations and circulating concentrations of cardiovascular disease risk factors, such as soluble adhesion molecules (sE-selectin, sICAM-1 and sVCAM-1), a chemokine monocyte chemoattractant protein (MCP)-1, plasminogen activator inhibitor-1, and fatty acid-binding protein 4, in type 2 diabetic patients for 3 months.

Methods: We enrolled 47 Japanese patients with type 2 diabetes, with HbA1c levels with 7.26 ± 0.5 % (mean ± standard deviation), and who were treated with the highest approved dose of acarbose (100 mg/meal) or voglibose (0.3 mg/meal) in combination with insulin or sulfonylurea. Patients' prior α-GIs were switched to a medium dose of miglitol (50 mg/meal), and the new treatments were maintained for 3 months. Thirty-five patients who completed the 3-month study and provided serum samples were analyzed.

Results: The switch to miglitol for 3 months did not affect HbA1c, fasting glucose, triglycerides, total-cholesterol or C-reactive protein levels, or result in any adverse events. Glucose fluctuations were significantly improved by the change in treatment (M-value: 10.54 ± 4.32 to 8.36 ± 2.54), while serum protein concentrations of MCP-1 (525.04 ± 288.06-428.11 ± 163.78 pg/mL) and sE-selectin (18.65 ± 9.77-14.50 ± 6.26 ng/mL) were suppressed.

Conclusion: Our results suggest that switching from acarbose or voglibose to miglitol for 3 months suppressed glucose fluctuations and serum protein levels of MCP-1 and sE-selectin in type 2 diabetic Japanese patients, with fewer adverse effects.

Citing Articles

Quinazolinone-1,2,3-triazole-acetamide conjugates as potent α-glucosidase inhibitors: synthesis, enzyme inhibition, kinetic analysis, and molecular docking study.

Moghadam Farid S, Iraji A, Mojtabavi S, Ghasemi M, Faramarzi M, Mahdavi M RSC Med Chem. 2023; 14(3):520-533.

PMID: 36970140 PMC: 10033893. DOI: 10.1039/d2md00297c.

Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.

Xu J, Rajaratnam R Cardiovasc Diabetol. 2017; 16(1):18.

PMID: 28148253 PMC: 5288947. DOI: 10.1186/s12933-017-0499-5.

References

Chiasson J, Josse R, Gomis R, Hanefeld M, Karasik A, Laakso M . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290(4):486-94. DOI: 10.1001/jama.290.4.486. View

Snell-Bergeon J, Wadwa R . Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther. 2012; 14 Suppl 1:S51-8. PMC: 3361183. DOI: 10.1089/dia.2012.0031. View

Kralisch S, Fasshauer M . Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?. Diabetologia. 2012; 56(1):10-21. DOI: 10.1007/s00125-012-2737-4. View

Mako V, Czucz J, Weiszhar Z, Herczenik E, Matko J, Prohaszka Z . Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS. Cytometry A. 2011; 77(10):962-70. DOI: 10.1002/cyto.a.20952. View

Haubner F, Lehle K, Munzel D, Schmid C, Birnbaum D, Preuner J . Hyperglycemia increases the levels of vascular cellular adhesion molecule-1 and monocyte-chemoattractant-protein-1 in the diabetic endothelial cell. Biochem Biophys Res Commun. 2007; 360(3):560-5. DOI: 10.1016/j.bbrc.2007.06.044. View

Matsumoto K, Fujishima K, Moriuchi A, Saishoji H, Ueki Y . Soluble adhesion molecule E-selectin predicts cardiovascular events in Japanese patients with type 2 diabetes mellitus. Metabolism. 2009; 59(3):320-4. DOI: 10.1016/j.metabol.2009.06.011. View

. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet. 1999; 354(9179):617-21. View

Cefalu W . Diabetes Care: “state of the union”. Diabetes Care. 2013; 36(1):1-3. PMC: 3526229. DOI: 10.2337/dc12-2182. View

Tsujino D, Nishimura R, Taki K, Morimoto A, Tajima N, Utsunomiya K . Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study. Diabetes Technol Ther. 2011; 13(3):303-8. DOI: 10.1089/dia.2010.0099. View

10.

Heinz G, Komjati M, Korn A, Waldhausl W . Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes. Eur J Clin Pharmacol. 1989; 37(1):33-6. DOI: 10.1007/BF00609420. View

11.

Kingma P, Menheere P, Sels J, Nieuwenhuijzen Kruseman A . alpha-Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care. 1992; 15(4):478-83. DOI: 10.2337/diacare.15.4.478. View

12.

Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M . Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2003; 25(1):10-6. DOI: 10.1016/s0195-668x(03)00468-8. View

13.

Kim C, Park H, Kawada T, Kim J, Lim D, Hubbard N . Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond). 2006; 30(9):1347-55. DOI: 10.1038/sj.ijo.0803259. View

14.

Kleemann R, Zadelaar S, Kooistra T . Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res. 2008; 79(3):360-76. PMC: 2492729. DOI: 10.1093/cvr/cvn120. View

15.

Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A . Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999; 22(6):920-4. DOI: 10.2337/diacare.22.6.920. View

16.

DeClercq V, Taylor C, Zahradka P . Adipose tissue: the link between obesity and cardiovascular disease. Cardiovasc Hematol Disord Drug Targets. 2008; 8(3):228-37. DOI: 10.2174/187152908785849080. View

17.

Takami S, Yamashita S, Kihara S, Matsuzawa Y . High concentration of glucose induces the expression of intercellular adhesion molecule-1 in human umbilical vein endothelial cells. Atherosclerosis. 1998; 138(1):35-41. DOI: 10.1016/s0021-9150(97)00286-4. View

18.

Osonoi T, Saito M, Mochizuki K, Fukaya N, Muramatsu T, Inoue S . The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus. Metabolism. 2010; 59(12):1816-22. DOI: 10.1016/j.metabol.2010.06.006. View

19.

Fujita Y, Tamada D, Kozawa J, Kobayashi Y, Sasaki S, Kitamura T . Successful treatment of reactive hypoglycemia secondary to late dumping syndrome using miglitol. Intern Med. 2012; 51(18):2581-5. DOI: 10.2169/internalmedicine.51.8171. View

20.

Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, Watada H . Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism. 2008; 57(9):1299-306. DOI: 10.1016/j.metabol.2008.04.027. View